Fierce Pharma

MAY 1, 2024

Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. | Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. The company plans to sell products such as its COVID treatment Paxlovid and a migraine nasal spray in this way, it told the Financial Times.

Marketing 312

Marketing Sales Medicine Leads 312

Pharmaceutical Technology

MAY 1, 2024

AstraZeneca has maintained that while the vaccine may, in “very rare” cases, cause TTS, the casual mechanism for this effect remains unknown.

145

145

MedCity News

MAY 1, 2024

Walmart’s decision to shutter its healthcare division reflects just how difficult it is to achieve profitability in the primary care and telehealth markets. Experts think retailers simply aren’t prepared to handle the bevy of challenges that come along with delivering healthcare — but could this news also be a sign of the system being broken? The post Healthcare Is a Frontier Not Even Walmart Could Conquer — And It’s Not Looking Great For Others Either appeared first on MedCity News.

Healthcare 139

Healthcare Healthcare Retail Marketing 139

pharmaphorum

MAY 3, 2024

Walgreens’ plans to disrupt the clinical trials sector have taken a step forward with a high-profile partnership with Boehringer Ingelheim

133

133

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

MAY 1, 2024

Just about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company. | Merely about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company. And it involves a major organizational restructuring.

Biopharma 343

Biopharma 343

Pharma IQ

APRIL 29, 2024

Discover how artificial intelligence is revolutionizing the field of precision medicine. In this insightful article, Tim O’Connor, Chief Data Scientist at Phenomix Sciences, discusses the pivotal role.

Medicine 130

Medicine 130

pharmaphorum

MAY 3, 2024

Apple gets FDA okay to use the atrial fibrillation history tool incorporated in some of its Apple Watch devices in clinical trials

FDA 126

FDA 126

Fierce Pharma

APRIL 29, 2024

The price tag includes both the approved cancer drug Qinlock and another Deciphera candidate heading to the FDA’s desk in the coming months.

338

338

Pharmaceutical Technology

MAY 2, 2024

From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.

Pharmaceutical 124

Pharmaceutical Leads 124

MedCity News

MAY 3, 2024

Hospitals’ operating margins and patient volumes dropped slightly in March. While hospitals were doing relatively well financially during the first quarter of the year, this new data could suggest more financial challenges ahead for hospitals. But right now, it’s unclear whether the recent declines in hospitals’ margins and volumes will be short- or long-term.

Patients 128

Patients 128

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

European Pharmaceutical Review

MAY 2, 2024

Interim results of an ongoing study published in The Lancet have reported that Beyfortus (nirsevimab) reduced respiratory syncytial virus (RSV) hospitalisations by 82 percent in infants under six months, compared to infants who received no RSV intervention. Sanofi noted that as a long-acting antibody, Beyfortus has been shown to provide rapid protection, helping to prevent lower respiratory tract disease caused by RSV without the immune system needing activation.

Manufacturing 122

Manufacturing Government Networking Pharmaceutical 122

Fierce Pharma

APRIL 30, 2024

The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. | The U.S. FTC is not done with its crackdown on what it views as improper listing of patents in the FDA Orange Book. After an initial round of challenge launched in November against more than 100 patents, the FTC is back targeting another 300-plus patent listings by eight pharma firms.

FDA 328

FDA Pharma 328

pharmaphorum

APRIL 30, 2024

For the last few years, Walmart has been promising to disrupt the US healthcare sector with a national network of clinics providing low-cost care and telehealth services. Now, it is reining back on those plans.

Healthcare 122

Healthcare Healthcare Networking 122

MedCity News

MAY 2, 2024

Mariana Oncology brings Novartis a lead radiopharmaceutical program in development for small cell lung cancer. The deal is the latest in a string of big pharma M&A moves in the red-hot radiopharmaceuticals space. The post Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition appeared first on MedCity News.

Pharma 128

Pharma Leads Biopharma 128

Advertisement

Pharmaceutical Technology

APRIL 28, 2024

Artificial intelligence tools can be used for infection control through facial recognition systems designed to identify proper face mask use within hospitals.

119

119

Fierce Pharma

APRIL 30, 2024

Biopharma companies and industry lobbying groups are striking out in their legal efforts to challenge price-cutting measures in the Inflation Reduction Act. | A federal judge tossed lawsuits by Bristol Myers Squibb and Johnson & Johnson, which questioned the constitutionality of the U.S. government requiring drugmakers to negotiate with Medicare on drug pricing.

Biopharma 321

Biopharma Government 321

pharmaphorum

APRIL 29, 2024

A partnership between Huma Therapeutics and Merck KGaA to develop digital support tools for cancer patients has borne fruit with the launch of a bladder cancer app in the UK

Patients 119

Patients 119

MedCity News

APRIL 30, 2024

Enlaza Therapeutics’ drugs form covalent bonds that lock the therapy onto its target. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies. The post J.P. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer appeared first on MedCity News.

Leads 128

Leads Safety Biopharma Pharma 128

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

European Pharmaceutical Review

MAY 2, 2024

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a policy paper on its strategic approach to artificial intelligence (AI). It summarises the MHRA’s view on the UK government’s white paper on AI regulation published in 2023. Following publication of this white paper, the government requested that the MHRA outline the steps the agency is working on in relation to its expectations.

Safety 115

Safety Medicine Government Medical 115

Fierce Pharma

MAY 1, 2024

It’s no secret that U.S. biopharma companies rely on Chinese contractors to provide lab research and drug manufacturing services. | Facing a push for China-U.S. decoupling from Washington, the industry trade group BIO now wants to quantify the U.S.’s dependence on Chinese CDMOs through a survey.

Biopharma 313

Biopharma Manufacturing 313

pharmaphorum

MAY 3, 2024

Some NHS patients in the UK will finally be able to access Pfizer’s sickle cell disease therapy Oxbryta after agreement was reached on a price cut

Patients 118

Patients 118

MedCity News

MAY 3, 2024

Amgen is confident its injectable obesity drug would have a differentiated profile compared to medications now on the market from Novo Nordisk and Eli Lilly and it’s now preparing for Phase 3 testing. But an oral obesity drug in Amgen’s pipeline will not advance beyond Phase 1. The post Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds appeared first on MedCity News.

Medical 128

Medical Marketing Biopharma Pharma 128

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

PharmaVoice

MAY 1, 2024

The FDA’s newly launched Center for Clinical Trial Innovation potentially opens the door for more efficient and expanded AI use, but leaves pharmas wanting more guidance.

Pharma 114

Pharma FDA 114

Fierce Pharma

MAY 2, 2024

Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics for the Danish company's popular GLP-1 drug. | Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics for the Danish company's popular GLP-1 drug.

Competition 310

Competition 310

pharmaphorum

MAY 2, 2024

Hospital staff in the UK have developed and piloted an app that can help patients monitor their progress to recovery after surgeries.

Patients 115

Patients 115

MedCity News

APRIL 28, 2024

Labcorp’s $239 million offer was selected as the winning bid for the assets of genetic testing company Invitae, which filed for bankruptcy protection earlier this year. The acquisition deal, Labcorp’s second in the past month, will enable it to expand in oncology and rare diseases. The post Labcorp Makes Another Acquisition, Plucking Invitae Assets From Bankruptcy Auction appeared first on MedCity News.

Biopharma 127

Biopharma 127

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

PharmaTimes

APRIL 29, 2024

The new process makes generating active pharmaceutical ingredients quicker and easier

Pharmaceutical 113

Pharmaceutical 113

Fierce Pharma

MAY 3, 2024

Shortly after Novo Holdings’ parent company elected to resubmit paperwork around the investment firm’s proposed $16.5 billion buyout of CDMO giant Catalent, the U.S. | Shortly after Novo Holdings’ parent company elected to resubmit paperwork around the investment firm’s proposed $16.5 billion buyout of CDMO giant Catalent, the U.S. Federal Trade Commission has teed up a further extension on the deal’s review period.

306

306

pharmaphorum

MAY 1, 2024

FTC sends more warnings to pharma companies over 'junk' patents to protect drugs from generic competition, including Novo Nordisk's Ozempic.

Competition 115

Competition Pharma 115

MedCity News

APRIL 30, 2024

The Drug Enforcement Agency’s decision to reclassify cannabis to a Schedule III drug could mark the first step in a long process to establish a new normal for medical cannabis care. The post Momentum is Building to Put Medical Cannabis into Mainstream Healthcare appeared first on MedCity News.

Medical 124

Medical Healthcare Healthcare 124

Advertisement

Distribution